New York State Psychiatric Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, New York State Psychiatric Institute sits in the top decile of US sponsors by registered trial count (#99 of 15,742 sponsors by registered trial count).
New York State Psychiatric Institute: 364 sponsored US clinical trials, 12 recruiting.
New York State Psychiatric Institute sponsors 364 registered US clinical trials on ClinicalTrials.gov, 12 of them currently recruiting, and 296 completed. 80 of these trials are in Phase 3-4 (later-stage) and 152 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 10 trials.
Top-decile sponsor footprint
New York State Psychiatric Institute ranks in the top decile of sponsors by registered trial count (#99 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
296 of 342 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
364 total, page 4 of 8
Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
NCT01951118
Personalized and Scalable Cognitive Remediation Approaches
NCT01945333
Ketamine for Suicidality in Bipolar Depression
NCT01944293
Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence
NCT01811940
Cognitive Behavior Therapy for Depression
NCT01868711
Gabapentin Treatment of Benzodiazepine Dependence
NCT01893632
TDCS for Auditory Hallucinations in Schizophrenia
NCT01898299
Mindfulness-Based Cognitive Therapy + Safety Planning For Suicidal Behavior
NCT01826240
NMDA Antagonists in Bipolar Depression
NCT01833897
Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers
NCT01740414
Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo
NCT01920802
Quetiapine Pharmacotherapy for Cannabis Dependence
NCT01697709
Attaining and Maintaining Wellness in Obsessive-compulsive Disorder
NCT01686087
Kuvan in People With Schizophrenia and Schizoaffective Disorder
NCT01706965
Developing New Clinical Management Strategies
NCT02082392
Cognitive Training for Memory Deficits Associated With Electroconvulsive Therapy
NCT01876758
Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil
NCT01845636
Study Comparing Magnetic Seizure Therapy (MST) to Electroconvulsive Therapy (ECT) for Depression in Older Adults
NCT01869374
Studying the Effects of Phentermine on Eating Behavior
NCT01886937
Cognitive Skills Training for Homeless Youth
NCT01815398
Ketamine in the Treatment of Suicidal Depression
NCT01700829
Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD
NCT01695291
The Influence of Aerobic Exercise on Cognitive Functioning in Schizophrenia.
NCT01897064
A Pilot Trial of Interpersonal Psychotherapy for the Treatment of Depression in Patients With Prostate, Colorectal, Lung and Pancreatic Cancer
NCT01940237
Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence
NCT01467999
Desvenlafaxine vs. Placebo Treatment of Chronic Depression
NCT01537068
The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence
NCT01535937
Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence
NCT01486810
Tranylcypromine Treatment of Bipolar Depression
NCT01430455
Combination Treatment Study for Memory Impairment and Depression
NCT01658228
A Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior
NCT01447602
A Stepped Care Model of Adolescent Depression Treatment in Primary Care
NCT01443715
Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD
NCT01415440
Behavioral Change in the Mother-Infant Dyad: Preventing Postpartum Depression
NCT01379781
Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder
NCT02048241
Wake Therapy in the Treatment of Depression
NCT01431573
Exercise, Age-Related Memory Decline, And Hippocampal Function
NCT01329653
Improved Strategies for Outpatient Opioid Detoxification
NCT01377610
Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders
NCT01519557
A Comparison of Long-acting Injectable Medications for Schizophrenia
NCT01136772
Pioglitazone for Heroin and for Nicotine Dependence
NCT01395797
Glutamatergic Modulation of Cocaine-related Deficits
NCT01790490
Nalrexone Facilitated Discontinuation of Buprenorphine
NCT01895036
Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172
NCT01222351
Alprazolam and Eating Behavior in Anorexia Nervosa
NCT01411813
Cognitive Benefits of Aerobic Exercise Across the Age Span
NCT01179958
Gabapentin for Abstinence Initiation in Alcohol Dependence
NCT01141049
Behavioral and Physiological Effects of Cocaine in Cocaine-dependent Participants Treated With Levodopa in Combination With Carbidopa and Entacapone (LCE)
NCT01437293
Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa
NCT01170117
Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone
NCT01395784
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 51 |
| Phase 2 | 101 |
| Phase 3 | 14 |
| Phase 4 | 66 |
Therapeutic Areas
What is open in the New York State Psychiatric Institute pipeline
12 recruiting of 364 indexed (3% open); 296 completed (81%).
Phase mix: 80 late (III/IV) vs 152 early (I/II) (early-phase heavy).
Top condition: Depression (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
New York State Psychiatric Institute: open-pipeline peers nationwide
Peers matched on 364 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
New York State Psychiatric Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 364 trials (± recruiting share)
- Roswell Park Cancer Institute · 365 trials · 16% recruiting
- UNC Lineberger Comprehensive Cancer Center · 366 trials · 22% recruiting
- University of California, Irvine · 368 trials · 20% recruiting
- Northwell Health · 370 trials · 22% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Biotronik · 3% recruiting · 30 trials
- Charles Drew University of Medicine and Science · 3% recruiting · 30 trials
- Kyntra Bio · 3% recruiting · 30 trials
- Halozyme Therapeutics · 3% recruiting · 31 trials
Related
What to do with this New York State Psychiatric Institute page
364 registered trials is a research-attention snapshot, not an endorsement of New York State Psychiatric Institute or any single study.
- 12 of New York State Psychiatric Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition New York State Psychiatric Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. New York State Psychiatric Institute pipeline card: 364 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.